Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma

NCT03318562 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT03318562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03318562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma
Lead sponsor
Effector Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 21, 2017
Completion date
January 22, 2019
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, triple negative breast cancer